sofidexFor patientsAre you a clinician? Clinical site
Ask Sofi
Listen
Patient SupportEmergencies & Reporting
Log inSign up

Meds & supplements  ›  Tesamorelin

Medicine

Tesamorelin

EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • Long-term cardiovascular safety of EGRIFTA WR has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue.
  • EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect.
  • There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA WR.

What it is used for

EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Limitations of Use:

  • Long-term cardiovascular safety of EGRIFTA WR has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue.
  • EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect.
  • There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA WR.

Side effects, and when to stop

The following important adverse reactions are also described elsewhere in the labeling:

  • Increased risk of neoplasms
  • Elevated IGF-1 levels
  • Fluid retention
  • Glucose intolerance or diabetes mellitus
  • Hypersensitivity reactions
  • Injection site reactions

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Tesamorelin; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/tesamorelin

APA 7th

sofidex. (2026, August 3). Tesamorelin. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/tesamorelin

AMA 11th

Tesamorelin. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/tesamorelin

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.